[Hyperhomocysteinemia and cardiometabolic risk].
Hyperhomocysteinemia, when considered as a causal factor of vascular diseases, has been subject of much discussion. Case-control, retrospective and prospective studies have identified a relationship between high plasma concentrations of homocysteine and vascular disease. The aim of the present review was to better understand the interrelation between plasma concentrations of homocysteine and vascular diseases, as well as the involvement of classical risk factors for the disease: genetic factors, such as mutations in the genes that codify the enzymes involved in the metabolism of homocysteine, and nutritional factors, such as complex B vitamin deficiency. The publications of the main databases in health were consulted for the period 1962 to 2009. The mechanism by which hyperhomocysteinemia acts as a risk factor for vascular diseases still has not been fully clarified, but involvement of endothelial dysfunction and lipid peroxidation is suggested. The treatment of hyperhomocysteinemia is based on food supplements and medication, with folic acid and vitamins B6 and B12.
Vannucchi
Helio
H
Divisão de Nutrologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP) Av. Bandeirantes, 3.900 14049-900 - Ribeirão Preto, SP, Brasil. hvannucc@fmrp.usp.br
Melo
Sandra Soares
SS
D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology*; D005492:Folic Acid / Q000627:therapeutic use; D006710:Homocysteine / Q000097:blood* / Q000235:genetics; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D012307:Risk Factors; D014805:Vitamin B 12 / Q000627:therapeutic use; D025101:Vitamin B 6 / Q000627:therapeutic use; D014804:Vitamin B Deficiency / Q000150:complications; D014815:Vitamins / Q000627:therapeutic use
D015415:Biomarkers; D014815:Vitamins; D006710:Homocysteine; D025101:Vitamin B 6; D005492:Folic Acid; D014805:Vitamin B 12